Glanbia Upgrades Full-Year Guidance as H1 Results Beat Expectations

Divisional Deep Dive: A Tale of Three Segments

Glanbia’s revised segment reporting (Health & Nutrition / Dairy Nutrition split from the old Glanbia Nutritionals) provides clearer insight.

1. Performance Nutrition (PN): Signs of Spring

• Revenue: $850.0m (-3.8% constant currency). Excluding non-core SlimFast and Body&Fit, the decline was a milder 1.5%.
• EBITDA Margin: 12.7% (down 490bps from HY 2024’s 17.7%), heavily pressured by whey costs.
• The Silver Lining: Sequential improvement through H1. The flagship Optimum Nutrition brand (67% of PN revenue) saw a slight LFL decline of 0.5% overall, but crucially delivered 2% growth in Q2 (Volume +1.5%, Price +0.5%). International markets grew, particularly Asia Pacific. PN Americas declined 8.7%, PN International grew 4.9%.
• Portfolio Pruning: Agreement reached for the sale of Body & Fit (Benelux DTC).
• Outlook: Margins expected to improve in H2. LFL revenue growth (ex non-core) guided at 2-3% for FY.

2. Health & Nutrition (H&N): The Standout Performer

• Revenue: $313.0m (+18.0% constant currency). Driven by strong volume growth (+6.9%) and acquisitions (+11.5%), partially offset by slight pricing (-0.4%).
• EBITDA Margin: 19.5% (up a healthy 260bps from 16.9% in HY 2024).
• Growth Drivers: Good momentum across both premix and flavour solutions, especially internationally. The integration of Flavor Producers (acquired April 2024) is complete and performing well.
• Strategic Move: Announced acquisition of Sweetmix, a Brazil-based nutritional premix player ($41m initial consideration), enhancing Latin American presence.
• Outlook: Mid-single-digit LFL revenue growth and upgraded EBITDA margin guidance (18-19%) for FY.

3. Dairy Nutrition (DN): Steady and Strong

• Revenue: $763.7m (+14.1% constant currency). Driven by both volume (+4.3%) and pricing (+9.8%) thanks to favourable dairy markets and strong whey protein demand.
• EBITDA Margin: 9.5% (up 50bps from 9.0% in HY 2024).
• Growth Drivers: Strong demand in protein solutions (especially high-protein ready-to-eat) and colostrum (gut health/immunity).
• Outlook: Continued profit growth expected alongside the Group’s US joint venture.

Capital Allocation: Rewarding Shareholders

Glanbia continues its disciplined approach:

• Dividend: Interim dividend increased by 10% to 17.20 Euro cents per share. Payout ratio target (25-35% of Adjusted EPS) maintained.
• Share Buybacks: €62.8 million returned via buybacks in H1 (5.1m shares at avg. €12.33). A further €50m programme is expected before year-end.
• Balance Sheet: Remains robust. Net debt of $650.0m (HY 2024: $645.4m), with net debt to adjusted EBITDA at a comfortable 1.28x (HY 2024: 1.22x). Significant liquidity headroom ($1.37bn committed facilities).
• Investment: Capital expenditure of $47.7m in H1. Full-year capex guided at $80m-$90m.

Leadership: Smooth Transition at the Top

A significant but orderly change is coming. Independent Non-Executive Director Paul Duffy has been appointed Chair Designate. He will succeed Donard Gaynor as Chair on 1 January 2026, with Gaynor retiring from the Board on 31 December 2025. Duffy brings substantial global consumer sector experience.

The Road Ahead: Upgraded Trajectory

Glanbia’s upgraded guidance speaks volumes about management’s confidence in the second-half recovery, particularly within PN as whey cost pressures ease and volume growth returns. The structural growth drivers in H&N and DN remain compelling.

The upcoming Capital Markets Day on 19th November will be key, promising an update on the Group’s medium-term growth agenda following its transformation programme (targeting $50m+ annual savings by 2027).

The bottom line? Glanbia navigated significant input cost headwinds in H1, particularly in PN, but delivered revenue growth and, crucially, saw improving trends within PN as the half progressed. The strength of H&N and DN provided ballast. Upgrading guidance in this environment signals resilience and operational execution. The market will now be keenly focused on the H2 PN margin recovery and the strategic vision laid out in November. One to watch.